Genmab Announce Positive Results for Daratumumab to Treat Multiple Myeloma
Genmab and their partner Johnson & Johnson have today announced positive mid-stage clinical data on daratumumab for multiple myeloma.
The preliminary results are from a 124-patient Phase II client trial of daratumumab in double refractory multiple myeloma conducted by J&J’s Janssen Biotech unit.
The results show an overall response rate of 29.2% in the 16 mg/kg dosing group. The median duration of response was 7.4 months.
The clinical study evaluated multiple myeloma patients who have received at least three different lines of therapy, including both a proteasome inhibitor and an immunomodulatory agent. Daratumumab showed a manageable safety profile.
Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab, commented: “we are very pleased with these positive results in this study of daratumumab as a monotherapy for the treatment of double refractory multiple myeloma,” adding “we look forward to presenting additional data of this trial at a key upcoming medical conference this year.”
The human CD38 monoclonal antibody was granted breakthrough therapy designation in May 2013 from the US Food and Drug Administration.